Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives

A compound and pharmaceutically acceptable salts having the species formula (3) ##STR28## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;

• wherein A is selected from the group consisting of nitrogen, carbon and sulfur and B equals carbon when A is selected from the group consisting of sulfur, carbon and nitrogen or B equals nitrogen when A equals carbon and B equals sulfur when A equals carbon;
• wherein R.sub.3 is one of either hydrogen or methyl;
• wherein R.sub.4 is one of either hydrogen or a first lower alkyl group except wherein A equals sulfur wherein R.sub.4 is zero;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a second lower alkyl group which is the same or different from the first lower alkyl group;
• except when B is equal to sulfur wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a third lower alkyl group which is the same or different than the first lower alkyl group, and the second lower alkyl group, and the second lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, an alicyclic hydrocarbon, a substituted diaryl group and a substituted triaryl group, and each substituent of the substituted aryl group diaryl group, and triaryl group or the substituted alkylaryl group, alkyldiaryl group and alkyltriaryl group is the same or different and is selected from the group consisting of a fourth lower alkyl group which is the same as or different from the first lower alkyl group, the second lower alkyl group, the third lower alkyl group, an alkoxy, an alkoxyaryloxy group and a halogen.

A compound and pharmaceutically acceptable salts having the formula (6):

• ##STR29## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;
• wherein B is selected from the group consisting of nitrogen, carbon, sulfur and oxygen;
• wherein R.sub.3 is one of either hydrogen or methyl;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a first lower alkyl group except when B is one of either sulfur or oxygen wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a second lower alkyl group which is the same or different than the first lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, an alicyclic hydrocarbon,, a substituted diaryl group and a substituted triaryl group and each substituent of the substituted aryl group, diaryl group, triaryl group or the substituted alkylaryl group, alkyldiaryl group and alkyltriaryl group is the same or different and is selected from the group consisting of a third lower alkyl group which is the same as or different from the first lower alkyl group, the second lower alkyl group, an alkoxy, an alkoxyaryloxy group and a halogen.

A method of therapeutically treating a patient for an illness consisting of employing a compound and pharmaceutically acceptable salts thereof having the generic formula (2):

• ##STR30## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;
• wherein Z is one of either nitrogen or carbon and Q is one of either nitrogen or carbon but when Z equal nitrogen, Q does not equal nitrogen and when Q equals nitrogen, Z does not equal nitrogen;
• wherein A is selected from the group consisting of nitrogen, carbon and sulfur and B equals carbon when A is selected from the group consisting of sulfur, carbon, and nitrogen, B equals nitrogen when A equals carbon and B equals sulfur when A equals carbon;
• wherein R.sub.3 is one of either hydrogen or methyl except where Z is nitrogen wherein R.sub.3 is zero;
• wherein R.sub.4 is one of either a hydrogen or a first lower alkyl group except when A equals sulfur wherein R.sub.4 is zero;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a second lower alkyl group which is the same or different than said first lower alkyl group except when B is equal to sulfur wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a third lower alkyl group which is the same or different than said first lower alkyl group and said second lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, a substituted diaryl group and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a fourth lower alkyl group which is the same as or different than said first lower alkyl group, said second lower alkyl group, said third lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• which comprises:
• incorporating said compound in a suitable pharmaceutical carrier, administering a therapeutically effective amount of said compound incorporated in said carrier to a patient;
• and
• employing said method in therapeutically treating a patient for an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.

A method of prophylactically administering to a patient a compound and pharmaceutically acceptable salt thereof having the generic formula (2) ##STR31## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;

• wherein Z is one of either nitrogen or carbon and Q is one of either nitrogen or carbon but when Z equal nitrogen, Q does not equal nitrogen and when Q equals nitrogen, Z does not equal nitrogen;
• wherein A is selected from the group consisting of nitrogen, carbon and sulfur and B equals carbon when A is selected from the group consisting of sulfur, carbon, and nitrogen, B equals nitrogen when A equals carbon and B equals sulfur when A equals carbon;
• wherein R.sub.3 is one of either hydrogen or methyl except where Z is nitrogen wherein R.sub.3 is zero;
• wherein R.sub.4 is one of either a hydrogen or a first lower alkyl group except when A equals sulfur wherein R.sub.4 is zero;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a second lower alkyl group which is the same or different than said first lower alkyl group except when B is equal to sulfur wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a third lower alkyl group which is the same or different than said first lower alkyl group and said second lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, a substituted diaryl group and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a fourth lower alkyl group which is the same as or different than said first lower alkyl group, said second lower alkyl group, said third lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• which comprises:
• incorporating said compound in a suitable pharmaceutical carrier;
• administering a prophylactically effective amount of said compound incorporated in said carrier to a patient who is immunocompromised;
• and
• employing said method in prophylactically treating a patient to provide protection against an illness selected from the group consisting of Pneumocystis Carinii and Toxoplasmosis gondii.

A method of prophylactically administering to a patient a compound and pharmaceutically acceptable salt thereof having the species formula (3) ##STR32## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;

• wherein A is selected from the group consisting of nitrogen, carbon and sulfur and B equals carbon when A is selected from the group consisting of sulfur, carbon and nitrogen or B equals nitrogen when A equals carbon and B equals sulfur when A equals carbon;
• wherein R.sub.3 is one of either hydrogen or methyl;
• wherein R.sub.4 is one of either hydrogen or a first lower alkyl group except wherein A equals sulfur wherein R.sub.4 is zero;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a second lower alkyl group which is the same or different from the first lower alkyl group;
• except when B is equal to sulfur wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a third lower alkyl group which is the same or different than the first lower alkyl group, and the second lower alkyl group, and the second lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, a substituted diaryl group and a substituted triaryl group, and each substituent of the substituted aryl group diaryl group, and triaryl group or the substituted alkylaryl group, alkyldiaryl group and alkyltriaryl group is the same or different and is selected from the group consisting of a fourth lower alkyl group which is the same as or different from the first lower alkyl group, the second lower alkyl group, the third lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• which comprises:
• incorporating said compound in a suitable pharmaceutical carrier;
• administering a prophylactically effective amount of said compound incorporated in said carrier to a patient who is immunocompromised;
• and
• employing said method in prophylactically treating a patient to provide protection against an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.

A method of therapeutically treating a patient for an illness consisting of employing a compound and pharmaceutically acceptable salts thereof having the generic formula (6):

• ##STR33## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;
• wherein B is selected from the group consisting of nitrogen, carbon, sulfur and oxygen;
• wherein R.sub.3 is one of either hydrogen or methyl;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, an aldehyde, a first lower alkyl group except when B is one of either sulfur or oxygen wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a second lower alkyl group which is the same or different than the first lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, a substituted diaryl group and a substituted triaryl group and each substituent of the substituted aryl group, diaryl group, triaryl group or the substituted alkylaryl group, alkyldiaryl group and alkyltriaryl group is the same or different and is selected from the group consisting of a third lower alkyl group which is the same as or different from the first lower alkyl group, the second lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• which comprises:
• incorporating said compound in a suitable pharmaceutical carrier, administering a therapeutically effective amount of said compound incorporated in said carrier to a patient;
• and
• employing said method in therapeutically treating a patient for an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.

A method of prophylactically administering to a patient a compound and pharmaceutically acceptable salt thereof having the generic formula (6):

• ##STR34## wherein X and Y may be the same or different and are selected from the group consisting of OH and NH.sub.2 ;
• wherein B is selected from the group consisting of nitrogen, carbon, sulfur and oxygen;
• wherein R.sub.3 is one of either hydrogen or methyl;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a nitroso group, a formyl group, a first lower alkyl group except when B is one of either sulfur or oxygen wherein R.sub.1 is zero;
• and wherein R.sub.2 is selected from the group consisting of a second lower alkyl group which is the same or different than the first lower alkyl group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alkyltriaryl group, a substituted diaryl group and a substituted triaryl group and each substituent of the substituted aryl group, diaryl group, triaryl group or the substituted alkylaryl group, alkyldiaryl group and alkyltriaryl group is the same or different and is selected from the group consisting of a third lower alkyl group which is the same as or different from the first lower alkyl group, the second lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• which comprises:
• incorporating said compound in a suitable pharmaceutical carrier;
• administering a prophylactically effective amount of said compound incorporated in said carrier to a patient who is immunocompromised;
• and
• employing said method in prophylactically treating a patient to provide protection against an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.